Navigation Links
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers
Date:7/23/2014

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. 

Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the viability, proliferation and migration of these cancer cells.

Idelalisib is an oral therapy indicated in combination with rituximab, a monoclonal antibody, for patients with relapsed or refractory CLL for whom rituximab alone would be considered appropriate therapy. In October 2013, a Phase 3 study evaluating idelalisib in combination with rituximab in previously-treated CLL patients not fit for standard chemotherapy was stopped early because interim analysis was showing significant improvement in progression-free survival as well as median overall survival compared to placebo plus rituximab.

Idelalisib was also approved today as a monotherapy for patients with relapsed FL and SLL who have received at least two prior systemic therapies. FDA granted accelerated approval for FL and SLL based on overall response rate. 

"We have been eagerly awaiting the approval of this therapy as these are patients for whom there are few other good treatment options," said Lee Greenberger, Ph.D., LLS's chief scientific officer. "LLS funded research contributed to the understanding of the PI3K pathway in B cell malignancies beginning in 1999; this allowed the identification and clinical development of inhibitors of this target. LLS exists to find cures and ensure access to treatments for blood cancer patients, and any new advance that brings the potential to help save more lives is good news."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

Contact: Andrea Greif
Senior Director of Communications
(914)821-8958 (p)
914)772-3027 (c)
andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
2. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. New Study Finds Targeted Treatment Can Significantly Reduce Relapse Risk In High-Risk Children With Acute Myeloid Leukemia
7. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
8. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
9. Polaris Group Files New IND for ADI-PEG 20 in Leukemia
10. The Leukemia & Lymphoma Society Applauds FDAs Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma
11. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... 2017  Getinge, a leading global provider of ... and cost efficiency within healthcare and life sciences, ... practice demonstrating that intra-aortic balloon counterpulsation (IABC) appears ... patients. The single-center, retrospective, observational study showed that ... ® 50cc intra-aortic balloon (IAB) in contemporary ...
(Date:5/2/2017)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... Tech Reimbursement Consulting AB that allows for the ... AB,s proprietary market analyses through the MarketResearch.com website. ... world easy access to complete product descriptions and tables ...
(Date:5/2/2017)... CORALVILLE, Iowa , May 2, 2017 /PRNewswire/ ... innovative, patient-centric radiotherapy solutions, announced today that ... has been with CIVCO since 2012 and has ... line management, senior vice president and general manager, ... manager. "I am extremely proud of ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... ... in which the endometrial lining of the uterus spreads into the pelvic ... experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding may have ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/23/2017)... York City (PRWEB) , ... May 23, 2017 ... ... (EHR), Population Health and Clinical Integration company, announced today that its iClinic ... Medical Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... By all indications, and due ... County. While officials call for diligence, asking homeowners to scout for any open water ... concerns. Along with the annoying buzz of mosquitos is the buzz associated with potential ...
Breaking Medicine News(10 mins):